Log Out

Edwards Lifesciences (NYSE:EW) PT Lowered to $112.00 at Truist Financial

kopsource · Sep 25, 2022 03:41

Edwards Lifesciences (NYSE:EW – Get Rating) had its price target decreased by Truist Financial from $117.00 to $112.00 in a research report released on Thursday, The Fly reports. Truist Financial currently has a buy rating on the medical research company's stock.

A number of other research analysts also recently issued reports on the company. Stifel Nicolaus cut their price target on Edwards Lifesciences from $128.00 to $115.00 in a report on Monday, July 18th. Cowen cut their price target on Edwards Lifesciences from $140.00 to $125.00 in a report on Monday, July 11th. StockNews.com upgraded Edwards Lifesciences from a hold rating to a buy rating in a report on Wednesday, August 17th. Canaccord Genuity Group downgraded Edwards Lifesciences from a buy rating to a hold rating and cut their price target for the company from $115.00 to $106.00 in a report on Friday, July 29th. Finally, Cowen cut their price target on Edwards Lifesciences from $140.00 to $125.00 in a report on Monday, July 11th. Three analysts have rated the stock with a hold rating and nineteen have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of Moderate Buy and an average price target of $125.81.

Get Edwards Lifesciences alerts:

Edwards Lifesciences Trading Up 0.7 %

EW opened at $84.74 on Thursday. The stock's fifty day moving average is $97.09 and its two-hundred day moving average is $101.68. The company has a market capitalization of $52.53 billion, a P/E ratio of 36.68, a PEG ratio of 2.49 and a beta of 1.14. Edwards Lifesciences has a 52 week low of $82.92 and a 52 week high of $131.73. The company has a quick ratio of 2.60, a current ratio of 3.37 and a debt-to-equity ratio of 0.10.

Edwards Lifesciences (NYSE:EW – Get Rating) last released its quarterly earnings data on Thursday, July 28th. The medical research company reported $0.63 EPS for the quarter, hitting the consensus estimate of $0.63. The company had revenue of $1.37 billion for the quarter, compared to the consensus estimate of $1.40 billion. Edwards Lifesciences had a return on equity of 24.77% and a net margin of 27.18%. Edwards Lifesciences's quarterly revenue was down .2% on a year-over-year basis. During the same period last year, the business posted $0.64 EPS. Analysts forecast that Edwards Lifesciences will post 2.51 earnings per share for the current year.

Insider Activity

In other news, CEO Michael A. Mussallem sold 19,875 shares of the business's stock in a transaction dated Thursday, July 14th. The stock was sold at an average price of $95.88, for a total value of $1,905,615.00. Following the completion of the transaction, the chief executive officer now owns 166,853 shares of the company's stock, valued at approximately $15,997,865.64. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other news, CEO Michael A. Mussallem sold 19,875 shares of the business's stock in a transaction dated Thursday, July 14th. The stock was sold at an average price of $95.88, for a total value of $1,905,615.00. Following the completion of the transaction, the chief executive officer now owns 166,853 shares of the company's stock, valued at approximately $15,997,865.64. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Bernard J. Zovighian sold 4,811 shares of the business's stock in a transaction dated Friday, August 5th. The shares were sold at an average price of $103.66, for a total value of $498,708.26. Following the completion of the transaction, the vice president now directly owns 21,247 shares of the company's stock, valued at approximately $2,202,464.02. The disclosure for this sale can be found here. Insiders sold a total of 86,128 shares of company stock valued at $8,223,839 in the last quarter. 1.29% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Edwards Lifesciences

Several institutional investors and hedge funds have recently modified their holdings of the business. B. Riley Wealth Management Inc. increased its stake in shares of Edwards Lifesciences by 45.9% in the 2nd quarter. B. Riley Wealth Management Inc. now owns 4,360 shares of the medical research company's stock valued at $415,000 after purchasing an additional 1,372 shares in the last quarter. Royal London Asset Management Ltd. increased its stake in shares of Edwards Lifesciences by 13.1% in the 2nd quarter. Royal London Asset Management Ltd. now owns 814,853 shares of the medical research company's stock valued at $77,545,000 after purchasing an additional 94,587 shares in the last quarter. Columbia Asset Management purchased a new position in shares of Edwards Lifesciences in the 2nd quarter valued at about $281,000. Stock Yards Bank & Trust Co. purchased a new position in shares of Edwards Lifesciences in the 2nd quarter valued at about $373,000. Finally, Legal & General Group Plc increased its stake in shares of Edwards Lifesciences by 2.8% in the 2nd quarter. Legal & General Group Plc now owns 4,984,192 shares of the medical research company's stock valued at $473,950,000 after purchasing an additional 134,421 shares in the last quarter. Hedge funds and other institutional investors own 81.33% of the company's stock.

About Edwards Lifesciences

(Get Rating)

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases.

Edwards Lifesciences (NYSE:EW) PT Lowered to $112.00 at Truist Financial

Edwards Lifesciences Trading Up 0.7 %

Insider Activity

Hedge Funds Weigh In On Edwards Lifesciences

About Edwards Lifesciences

See Also

Risk Disclaimer